Transparency notification Wellington

Brussels (Belgium), 18 May 2022 – 18:00 (CEST) – Regulated information 

1.  Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification from Wellington Management Group LLP (having its registered offices at 280 Congress Street, Boston, MA 02210, USA) on 16 May 2022. 

Wellington Management Group LLP has notified that, following an acquisition of UCB shares with voting rights by its affiliates, its shareholding in UCB SA/NV has increased and it has crossed the 7.5% threshold, on 13 May 2022.

On 13 May 2022, Wellington Management Group LLP (taking into account the holding of its affiliates) owned 15 166 845 UCB shares with voting rights, representing 7.80% of the total number of shares issued by the company (194 505 658), versus 7.46% (14 516 633 UCB shares) in the previous notification dated 2 September 2021.

2.  Content of the notification

• Reason for the notification: Acquisition or disposal of voting securities or voting rights. 
• Notification by: A parent undertaking or a controlling person.
• Persons subject to the notification requirement: 

 

• Date on which the threshold is crossed: 13 May 2022. 
• Threshold crossed (in %): 7.5%.
• Denominator: 194 505 658.

• Notified details:

 

• Chain of controlled undertakings through which the holding is effectively held:

• Additional information: Wellington Management Company LLP, Wellington Management International Ltd and Wellington Management Europe GmbH are investment management companies and can exercise the voting rights at their discretion in the absence of specific instructions from the beneficial owners of the shares.

3.  Further information 

This press release and the detailed transparency notification are available on UCB SA/NV’s website via the following link.

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV’s website via the following link.

For further information, contact UCB: 

Investor Relations
Antje Witte 
T +32 2 559 94 14
antje.witte@ucb.com

Corporate Communications
Laurent Schots 
T+32 2 559 92 64
laurent.schots@ucb.com     

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 600 people in nearly 40 countries, the company generated revenue of € 5.8 billion in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news